• NF449 and Selective Platelet P2X1 Blockade

  2026-09-14

  The reference study established NF449 as a concentration-dependent antagonist with substantially greater activity at platelet P2X1 than at P2Y1 or P2Y12 under the tested conditions. By combining human platelet assays with mouse thrombosis models, it linked P2X1 blockade to reduced platelet activation and thrombus formation while examining whether hemostasis was preserved.

• PNU 74654: Wnt Signaling for Cell-Fate Studies

  2026-09-14

  PNU 74654 is a Wnt signaling pathway inhibitor for investigating β-catenin-dependent cell fate, proliferation, and differentiation. This evidence-led guide explains how to use it without overextending findings from muscle biology into cancer research or stem cell research.

• SM-102 for mRNA Delivery: Workflow & Optimization

  2026-09-13

  SM-102 provides a practical ionizable-lipid starting point for mRNA vaccine delivery system development, with defined solubility, purity, and storage requirements. This guide translates published machine-learning and animal-validation findings into a controlled LNP workflow, comparison strategy, and troubleshooting plan.

• Cy5 Goat Anti-Mouse IgG (H+L) Guide

  2026-09-12

  The Cy5 Goat Anti-Mouse IgG (H+L) Antibody is a Cy5-conjugated secondary antibody for fluorescent mouse IgG detection in IHC, ICC, and flow cytometry. Its affinity-purified polyclonal design supports sensitive signal amplification when assay controls, species compatibility, and light-protected storage are maintained.

• Zosuquidar for P-gp Resistance Assays

  2026-09-11

  Zosuquidar (LY335979) converts P-glycoprotein activity from a confounding variable into a testable mechanism in chemotherapy and degrader-resistance studies. This workflow-focused guide shows how to distinguish true multidrug-resistance reversal from nonspecific toxicity, with practical designs for AML, lymphoma, and ABCB1-driven resistance models.

• Caveolin-1, Cholesterol, and MASLD Progression

  2026-09-11

  The reference study identifies Caveolin-1 as a regulator of hepatic cholesterol homeostasis that limits endoplasmic reticulum stress and pyroptosis during metabolic dysfunction-associated steatotic liver disease. By combining CAV1-deficient mouse models, liver transcriptomics, human samples, and cell-based validation, the authors connect CAV1 with the FXR/NR1H4–ABCG5/ABCG8 axis and provide a mechanistic framework for interpreting cholesterol accumulation in MASLD.

• FerroOrange Maps Fe²⁺ in Macrophage Ferroptosis

  2026-09-10

  FerroOrange provides a live-cell Fe²⁺ fluorescent probe for connecting intracellular iron accumulation with macrophage ferroptosis. This article explains how to interpret the PM2.5–Fra2/LCN2 pathway, design complementary assays, and avoid confusing Fe²⁺ signals with ferroptosis itself.

• 2-NBDG Glucose Uptake Assay Kit Workflow

  2026-09-10

  The 2-NBDG Glucose Uptake Assay Kit converts transporter-mediated glucose entry into a rapid, non-radioactive fluorescence readout suitable for plate-based and single-cell experiments. It is especially useful for connecting glucose metabolism research with treatment response, while phloretin and PI support specificity and viability-aware interpretation.

• Tiamulin: Veterinary Research Workflows

  2026-09-09

  Tiamulin (Thiamutilin) combines strain-focused antibacterial activity with investigational anti-inflammatory effects, making it useful for integrated pathogen, cell-signaling, and PK/PD studies. This workflow shows how to formulate, dose, measure, and troubleshoot the compound while avoiding clinically important ionophore interactions.

• AZD3463: A Translational Blueprint for ALK Inhibition

  2026-09-09

  AZD3463 offers a strategic model for translating dual ALK/IGF1R inhibition into genotype-aware neuroblastoma research, with evidence spanning pathway suppression, apoptosis, chemotherapy sensitization, and orthotopic xenografts.

• γH2AX: From DNA Damage Signal to Translation

  2026-09-08

  A thought-leadership guide to using γH2AX as a mechanistic and translational readout in radiation oncology, with practical guidance for evaluating EGCG nanoparticle-enhanced FLASH-RT and selecting a robust immunofluorescence workflow.

• Relative vs Fractional Viability in Cancer Drug Testing

  2026-09-08

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. By separating growth inhibition from cell killing and considering their different timing, the work provides a more informative framework for interpreting in vitro drug-response experiments.

• 25-Hydroxycholesterol Reprograms TAM Immunity

  2026-09-07

  Xiao et al. identify CH25H and lysosome-accumulated 25-hydroxycholesterol as an immunometabolic checkpoint that activates AMPKα and reinforces STAT6-dependent ARG1 production in tumor-associated macrophages. The study connects oxysterol compartmentalization with macrophage-mediated immune suppression and shows that targeting CH25H can improve antitumor immunity, including responses to anti-PD-1 therapy.

• Topotecan HCl Workflow for Cancer Assays

  2026-09-07

  Build more informative cancer-drug assays with Topotecan HCl by separating growth inhibition from actual cell killing. This workflow connects concentration and exposure schedules with orthogonal readouts for lung, breast, and prostate cancer models while highlighting practical formulation and troubleshooting decisions.

• Epigenetic Immune Signatures in Melanoma

  2026-09-05

  Anichini et al. compared five epigenetic drug classes and found that guadecitabine most consistently activated immune-related transcriptional programs in melanoma, including innate TLR, NF-κB, and interferon-associated pathways. The study links tumor-cell epigenetic remodeling with patient biopsy responses and provides a framework for selecting epigenetic partners for immune checkpoint blockade.

8474 records 1/565 page Next 12345 下5页 Last page